Filipe Nery

Filipe Nery

Auto-generated profile, based on publicly available information

Filipe Nery

Immuno-Physiology and Pharmacology Department, School of Medicine and Biomedical Sciences, University of Porto, Portugal

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2015 in Hepatology
Verified
Journal Article
Closed access
PDF file
FNFilipe Nery
Filipe Nery
SCSylvie Chevret
Sylvie Chevret
BCBertrand Condat
Bertrand Condat
EREmmanuelle de Raucourt
Emmanuelle de Raucourt
LBLarbi Boudaoud
Larbi Boudaoud
OHOn Behalf Of Groupe D'Etude Et de Traitement du Carcinome Hépatocellulaire
On Behalf Of Groupe D'Etude Et de Traitement du Carcinome Hépatocellulaire

1 May 2019 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AGAndrea De Gottardi
Andrea De Gottardi
PRPierre-Emmanuel Rautou
Pierre-Emmanuel Rautou
JSJeoffrey Schouten
Jeoffrey Schouten
LRLaura Rubbia-Brandt
Laura Rubbia-Brandt
FLFrank Leebeek
Frank Leebeek
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán

1 October 2016 in Gastroenterology
Verified
Journal Article
Closed access
SSShiv K. Sarin
Shiv K. Sarin
CPCyriac A. Philips
Cyriac A. Philips
PKPatrick S. Kamath
Patrick S. Kamath
ACAshok Choudhury
Ashok Choudhury
HMHitoshi Maruyama
Hitoshi Maruyama
DVDominique Valla
Dominique Valla

22 January 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
FNFilipe Nery
Filipe Nery
SCSofia Correia
Sofia Correia
CMCarlos Macedo
Carlos Macedo
JGJudit Gandara
Judit Gandara
VLVítor Lopes
Vítor Lopes
DVDominique Valla
Dominique Valla
Summary: Background: Nonmalignant portal vein thrombosis is a significant event in the course of cirrhosis that can contraindicate liver transplantation and even impact survival after the surgical procedure. Risk factors are not completely known or validated and are still debated.Aim: To identify in patients with cirrhosis the risk factors for portal vein thrombosis that are assessable in clinical practice.Methods: Between January 2014 and February 2017, 108 outpatients with cirrhosis and no portal vein thrombosis (78% Child A) were enrolled. Doppler ultrasound was performed every 3 or 6 months, for a median follow up of 19 months.Results: Portal vein thrombosis developed in 11 patients. Nonselective beta‐blockade (hazard ratio [HR] 10.56; 95% confidence interval [CI]: 1.35‐82.73; P = 0.025), and medium or large‐sized oesophageal varices (HR 5.67; 95% CI: 1.49‐21.63; P = 0.011) at baseline were associated with portal vein thrombosis development. Although heart rate (P < 0.001) and portal blood flow velocity at baseline (P = 0.005) were significantly reduced by nonselective beta‐blockers, they were not related to portal vein thrombosis development.Conclusions: Our findings confirm an association between portal vein thrombosis development and oesophageal varices at baseline, but suggest that the association could be explained by exposure to nonselective beta‐blockers, independently from effects on heart rate and portal blood flow velocity. The mechanisms that explain portal vein thrombosis development in patients on nonselective beta‐blockers require elucidation in order to optimise targeting of nonselective beta‐blockade in patients with cirrhosis.

23 August 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
MMMarta Magaz
Marta Magaz
HGHeloïse Giudicelli-Lett
Heloïse Giudicelli-Lett
JAJuan G. Abraldes
Juan G. Abraldes
OFOANA FARCAU-NICOARA
OANA FARCAU-NICOARA
FTFanny Turon
Fanny Turon
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán

4 May 2023 in JHEP Reports
Verified
Journal Article
Open access
Zhaohui BaiZhaohui Bai
Zhaohui Bai
NMNahum Méndez-Sánchez
Nahum Méndez-Sánchez
FRFernando Romeiro
Fernando Romeiro
AMAndrea Mancuso
Andrea Mancuso
CPCyriac Abby Philips
Cyriac Abby Philips
XQXingshun Qi
Xingshun Qi
Numerous studies have evaluated the role of human albumin (HA) in managing various liver cirrhosis-related complications. However, their conclusions remain partially controversial, probably because HA was evaluated in different settings, including indications, patient characteristics, and dosage and duration of therapy. Thirty-three investigators from 19 countries with expertise in the management of liver cirrhosis-related complications were invited to organise an International Special Interest Group. A three-round Delphi consensus process was conducted to complete the international position statement on the use of HA for treatment of liver cirrhosis-related complications. Twelve clinically significant position statements were proposed. Short-term infusion of HA should be recommended for the management of hepatorenal syndrome, large volume paracentesis, and spontaneous bacterial peritonitis in liver cirrhosis. Its effects on the prevention or treatment of other liver cirrhosis-related complications should be further elucidated. Long-term HA administration can be considered in specific settings. Pulmonary oedema should be closely monitored as a potential adverse effect in cirrhotic patients receiving HA infusion. Based on the currently available evidence, the international position statement suggests the potential benefits of HA for the management of multiple liver cirrhosis-related complications and summarises its safety profile. However, its optimal timing and infusion strategy remain to be further elucidated. Thirty-three investigators from 19 countries proposed 12 position statements on the use of human albumin (HA) infusion in liver cirrhosis-related complications. Based on current evidence, short-term HA infusion should be recommended for the management of HRS, LVP, and SBP; whereas, long-term HA administration can be considered in the setting where budget and logistical issues can be resolved. However, pulmonary oedema should be closely monitored in cirrhotic patients who receive HA infusion.